Sure, but what is the reason a lot of the bigger players are putting less into R&D and more into aquisitions buying up smaller micro-cap companies after they've managed to get to approval and then wear down shareprice before enevitably being bought out or sold off? What is the expense for the average drug to get from p1 through p3 and then through pdufa approval assuming it will only take a single submission for approval (Hi $HRTX and $OCUL, you fucking bastards)? What percent even make it all the way through p3?What sort of financing are we talking about? An offering to dilute sharholders? Saddle the company with so much debt it is coming out of their eyes?
Has this sector done very well compared to the broad market during the last 5 +/- years? Odd, if they're just jacking up prices sky high, hey?
No comments yet.